{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T09:47:05Z","timestamp":1791712025560,"version":"4.3.4"},"reference-count":92,"publisher":"Rambam Health Corporation","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rambam Maimonides Med J"],"DOI":"10.5041\/rmmj.10162","type":"journal-article","created":{"date-parts":[[2014,10,29]],"date-time":"2014-10-29T05:23:19Z","timestamp":1414560199000},"page":"e0028","source":"Crossref","is-referenced-by-count":179,"title":["Hematopoietic Stem Cell Transplantation\u201450 Years of Evolution and Future Perspectives"],"prefix":"10.5041","volume":"5","author":[{"given":"Israel","family":"Henig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsila","family":"Zuckerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2983","published-online":{"date-parts":[[2014,10,29]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1056\/NEJMp078166","article-title":"Hematopoietic-cell transplantation at 50","volume":"357","author":"Appelbaum","year":"2007","unstructured":"1. Appelbaum FR. Hematopoietic-cell transplantation at 50. N Engl J Med 2007;357:1472-5.","journal-title":"N Engl J Med"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/bmt.2008.424","article-title":"Allogeneic hematopoietic SCT for patients with autoimmune diseases","volume":"44","author":"Daikeler","year":"2009","unstructured":"2. Daikeler T, H\u00fcgle T, Farge D, et al. Allogeneic hematopoietic SCT for patients with autoimmune diseases. Bone Marrow Transplant 2009;44:27-33.","journal-title":"Bone Marrow Transplant"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1212\/01.wnl.0000240853.97716.24","article-title":"Allogeneic stem cell transplantation corrects biochemical derangements in MNGIE","volume":"67","author":"Hirano","year":"2006","unstructured":"3. Hirano M, Mart\u00ed R, Casali C, et al. Allogeneic stem cell transplantation corrects biochemical derangements in MNGIE. Neurology 2006;67:1458-60.","journal-title":"Neurology"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/bmt.2014.55","article-title":"Hematopoietic SCT in Europe: data and trends in 2012 with special consideration of pediatric transplantation","volume":"49","author":"Passweg","year":"2014","unstructured":"4. Passweg JR, Baldomero H, Peters C, et al. Hematopoietic SCT in Europe: data and trends in 2012 with special consideration of pediatric transplantation. Bone Marrow Transplant 2014;49:744-50.","journal-title":"Bone Marrow Transplant"},{"key":"ref4","unstructured":"5. Bone Marrow Donors Worldwide: Stem cell donor registries. Available at: https:\/\/www.bmdw.org\/ index.php?id=statistics_stemcell (Accessed June 18, 2014)."},{"key":"ref5","unstructured":"6. Pasquini MC, Wang Z. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR Summary Slides, 2013. Available at: http:\/\/ www.cibmtr.org\/ReferenceCenter\/SlidesReports\/SummarySlides\/Documents\/2013%20Summary%20Slides-%20Final%20Web%20Version%20%20V2% 204.14.2014.pptx (Accessed August 17, 2014)."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1634\/theoncologist.2013-0406","article-title":"Costs of allogeneic hematopoietic cell transplantation using reduced intensity conditioning regimens","volume":"19","author":"Khera","year":"2014","unstructured":"7. Khera N, Emmert A, Storer BE, Sandmaier BM, Alyea EP, Lee SJ. Costs of allogeneic hematopoietic cell transplantation using reduced intensity conditioning regimens. Oncologist 2014;19:639-44.","journal-title":"Oncologist"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.bbmt.2007.10.010","article-title":"Costs of allogeneic hematopoietic cell transplantation with high-dose regimens","volume":"14","author":"Saito","year":"2008","unstructured":"8. Saito AM, Cutler C, Zahrieh D, et al. Costs of allogeneic hematopoietic cell transplantation with high-dose regimens. Biol Blood Marrow Transplant 2008;14:197-207.","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"357","DOI":"10.7326\/0003-4819-13-2-357","article-title":"Aplastic anemia treated with daily transfusions and intravenous marrow; case report","volume":"13","author":"Osgood","year":"1939","unstructured":"9. Osgood EE, Riddle MC, Mathews TJ. Aplastic anemia treated with daily transfusions and intravenous marrow; case report. Ann Intern Med 1939;13:357-67.","journal-title":"Ann Intern Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1001\/archsurg.1950.01250010656001","article-title":"Effect of transplantation of bone marrow into irradiated animals","volume":"60","author":"Rekers","year":"1950","unstructured":"10. Rekers PE, Coulter MP, Warren SL. Effect of transplantation of bone marrow into irradiated animals. Arch Surg 1950;60:635-67.","journal-title":"Arch Surg"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1136\/bmj.2.4993.626","article-title":"Treatment of murine leukaemia with X rays and homologous bone marrow","volume":"2","author":"Barnes","year":"1956","unstructured":"11. Barnes DWH, Corp MJ, Loutit JF, Neal FE. Treatment of murine leukaemia with X rays and homologous bone marrow. Br Med J 1956;2:626-7.","journal-title":"Br Med J"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1056\/NEJM195709122571102","article-title":"Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy","volume":"257","author":"Thomas","year":"1957","unstructured":"12. Thomas ED, Lochte HL, Lu WC, Ferrebee JW. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N Engl J Med 1957;257:491-6.","journal-title":"N Engl J Med"},{"key":"ref12","unstructured":"13. Van Rood JJ. The detection of transplantation antigens in leukocytes. Semin Hematol 1968;5:187-214."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1182\/blood.V49.4.511.511","article-title":"One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation","volume":"49","author":"Thomas","year":"1977","unstructured":"14. Thomas ED, Buckner CD, Banaji M, et al. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood 1977;49:511-33.","journal-title":"Blood"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1056\/NEJM197909133011109","article-title":"Marrow transplantation for acute nonlymphoblastic leukemia in first remission","volume":"301","author":"Thomas","year":"1979","unstructured":"15. Thomas ED, Buckner CD, Clift RA, et al. Marrow transplantation for acute nonlymphoblastic leukemia in first remission. N Engl J Med 1979;301:597-9.","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1056\/NEJM198009043031007","article-title":"Transplantation of marrow from an unrelated donor to a patient with acute leukemia","volume":"303","author":"Hansen","year":"1980","unstructured":"16. Hansen JA, Clift RA, Thomas ED, Buckner CD, Storb R, Giblett ER. Transplantation of marrow from an unrelated donor to a patient with acute leukemia. N Engl J Med 1980;303:565-7.","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1056\/NEJMsa1311707","article-title":"registry","volume":"371","author":"Gragert","year":"2014","unstructured":"17. Gragert L, Eapen M, Williams E, et al. HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. N Engl J Med 2014;371:339-48.","journal-title":"N Engl J Med"},{"key":"ref17","unstructured":"18. Worldwide Network for Blood & Marrow Transplantation (WBMT). General information, bylaws, presentations. Available at: http:\/\/www.wbmt. org\/en\/general-information-bylaws-presentations\/ (Accessed June 3, 2014)."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/sj.bmt.1705366","article-title":"High-dose chemotherapy and autologous hematopoietic stem cell transplantation for metastatic breast cancer: a therapy whose time has passed","volume":"37","author":"DT","year":"2006","unstructured":"19. Vogl DT, Stadtmauer EA. High-dose chemotherapy and autologous hematopoietic stem cell transplantation for metastatic breast cancer: a therapy whose time has passed. Bone Marrow Transplant 2006; 37:985-7.","journal-title":"Bone Marrow Transplant"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"20. Benyamini N, Rowe JM. Is there a role for allogeneic transplantation in chronic myeloid leukemia? Expert Rev Hematol 2013;6:759-65.","DOI":"10.1586\/17474086.2013.849571"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/sj.bmt.1705970","article-title":"Emerging trends in transplantation of inherited metabolic diseases","volume":"41","author":"VK","year":"2008","unstructured":"21. Prasad VK, Kurtzberg J. Emerging trends in transplantation of inherited metabolic diseases. Bone Marrow Transplant 2008;41:99-108.","journal-title":"Bone Marrow Transplant"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"22. Atkins HL, Muraro PA, van Laar JM, Pavletic SZ. Autologous hematopoietic stem cell transplantation for autoimmune disease-is it now ready for prime time? Biol Blood Marrow Transplant 2012;18:S177-83.","DOI":"10.1016\/j.bbmt.2011.11.020"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1056\/NEJMoa1402888","article-title":"Autologous transplantation and maintenance therapy in multiple myeloma","volume":"371","author":"Palumbo","year":"2014","unstructured":"23. Palumbo A, Cavallo F, Gay F, et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med 2014;371:895-905.","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1182\/blood-2014-07-587519","article-title":"BFR (bendamustine, fludarabine and rituximab) allogeneic conditioning for chronic lymphocytic leukemia\/lymphoma: reduced risk of myelosuppression and severe graft-versus-host disease","volume":"124","author":"Khouri","year":"2014","unstructured":"24. Khouri IF, Wei W, Korbling M, et al. BFR (bendamustine, fludarabine and rituximab) allogeneic conditioning for chronic lymphocytic leukemia\/lymphoma: reduced risk of myelosuppression and severe graft-versus-host disease. Blood 2014;124: 2306-12.","journal-title":"Blood"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"3863","DOI":"10.1182\/blood-2013-07-514448","article-title":"Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI","volume":"122","author":"Copelan","year":"2013","unstructured":"25. Copelan EA, Hamilton BK, Avalos B, et al. Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. Blood 2013; 122:3863-70.","journal-title":"Blood"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1182\/blood.V75.3.555.555","article-title":"Graft-versus-leukemia reactions after bone marrow transplantation","volume":"75","author":"Horowitz","year":"1990","unstructured":"26. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990;75:555-62.","journal-title":"Blood"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1182\/blood.V76.12.2462.2462","article-title":"Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients","volume":"76","author":"Kolb","year":"1990","unstructured":"27. Kolb HJ, Mittermuller J, Clemm C, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990;76:2462-5.","journal-title":"Blood"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1182\/asheducation-2011.1.292","article-title":"Allogeneic immunotherapy to optimize the graft-versus-tumor effect: concepts and controversies","volume":"2011","author":"Porter","year":"2011","unstructured":"28. Porter DL. Allogeneic immunotherapy to optimize the graft-versus-tumor effect: concepts and controversies. Hematology Am Soc Hematol Educ Program 2011;2011:292-8.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1182\/blood.V91.3.756","article-title":"Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases","volume":"91","author":"Slavin","year":"1998","unstructured":"29. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998;91:756-63.","journal-title":"Blood"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1038\/sj.bmt.1702392","article-title":"Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma","volume":"25","author":"Nagler","year":"2000","unstructured":"30. Nagler A, Slavin S, Varadi G, Naparstek E, Samuel S, Or R. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma. Bone Marrow Transplant 2000;25:1021-8.","journal-title":"Bone Marrow Transplant"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1038\/sj.bmt.1702722","article-title":"Reduced-intensity allogeneic stem cell transplantation as salvage treatment for patients with indolent lymphoma or CLL after failure of autologous SCT","volume":"26","author":"Dreger","year":"2000","unstructured":"31. Dreger P, Glass B, Seyfarth B, et al. Reduced-intensity allogeneic stem cell transplantation as salvage treatment for patients with indolent lymphoma or CLL after failure of autologous SCT. Bone Marrow Transplant 2000;26:1361-2.","journal-title":"Bone Marrow Transplant"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.bbmt.2008.04.003","article-title":"Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: revised definitions to predict survival","volume":"14","author":"Weisdorf","year":"2008","unstructured":"32. Weisdorf D, Spellman S, Haagenson M, et al. Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: revised definitions to predict survival. Biol Blood Marrow Transplant 2008;14:748-58.","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"3447","DOI":"10.1200\/JCO.2005.09.117","article-title":"Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse","volume":"23","author":"Aversa","year":"2005","unstructured":"33. Aversa F, Terenzi A, Tabilio A, et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 2005;23:3447-54.","journal-title":"J Clin Oncol"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"34. Fuchs EJ. Haploidentical transplantation for hematologic malignancies: where do we stand? Hematology Am Soc Hematol Educ Program 2012;2012:230-6.","DOI":"10.1182\/asheducation.V2012.1.230.3798312"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1111\/j.1365-2141.2009.07883.x","article-title":"Improving outcomes of cord blood transplantation: HLA matching, cell dose and other graft- and transplantation-related factors","volume":"147","author":"Rocha","year":"2009","unstructured":"35. Rocha V, Gluckman E; Eurocord-Netcord Registry and European Blood and Marrow Transplant Group. Improving outcomes of cord blood transplantation: HLA matching, cell dose and other graft- and transplantation-related factors. Br J Haematol 2009;147: 262-74.","journal-title":"Br J Haematol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1182\/blood-2014-02-514760","article-title":"Hematopoietic stem cell transplantation donor sources in the 21st century: choosing the ideal donor when a perfect match does not exist","volume":"124","author":"Kekre","year":"2014","unstructured":"36. Kekre N, Antin JH. Hematopoietic stem cell transplantation donor sources in the 21st century: choosing the ideal donor when a perfect match does not exist. Blood 2014;124:334-43.","journal-title":"Blood"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1182\/blood.V82.7.1981.1981","article-title":"Syngeneic transplantation with peripheral blood mononuclear cells collected after the administration of recombinant human granulocyte colony-stimulating factor","volume":"82","author":"Weaver","year":"1993","unstructured":"37. Weaver CH, Buckner CD, Longin K, et al. Syngeneic transplantation with peripheral blood mononuclear cells collected after the administration of recombinant human granulocyte colony-stimulating factor. Blood 1993;82:1981-4.","journal-title":"Blood"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1038\/bmt.2012.258","article-title":"Surviving the cure: long term followup of hematopoietic cell transplant recipients","volume":"48","author":"NS","year":"2013","unstructured":"38. Majhail NS, Douglas Rizzo J. Surviving the cure: long term followup of hematopoietic cell transplant recipients. Bone Marrow Transplant 2013;48:1145-51.","journal-title":"Bone Marrow Transplant"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"39. Abdul Wahid SF, Ismail NA, Mohd-Idris MR, et al. Comparison of reduced-intensity and myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and acute lymphoblastic leukemia-A meta-analysis. Stem Cells Dev 2014 Sep 17. [Epub ahead of print]","DOI":"10.1089\/scd.2014.0123"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","unstructured":"40. Sorror ML. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005;106: 2912-19.","journal-title":"Blood"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.jgo.2014.04.003","article-title":"Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients","volume":"5","author":"Keller","year":"2014","unstructured":"41. Keller JW, Andreadis C, Damon LE, et al. Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients. J Geriatr Oncol 2014;5:238-44.","journal-title":"J Geriatr Oncol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/sj.bmt.1703178","article-title":"A randomised trial comparing cytomegalovirus antigenemia assay vs screening bronchoscopy for the early detection and prevention of disease in allogeneic bone marrow and peripheral blood stem cell transplant recipients","volume":"28","author":"Humar","year":"2001","unstructured":"42. Humar A, Lipton J, Welsh S, Moussa G, Messner H, Mazzulli T. A randomised trial comparing cytomegalovirus antigenemia assay vs screening bronchoscopy for the early detection and prevention of disease in allogeneic bone marrow and peripheral blood stem cell transplant recipients. Bone Marrow Transplant 2001;28:485-90.","journal-title":"Bone Marrow Transplant"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1093\/cid\/cit565","article-title":"Screening with serum galactomannan might be associated with better outcome than symptom-triggered galactomannan testing in allogeneic HSCT recipients with invasive aspergillosis","volume":"57","author":"Mikulska","year":"2013","unstructured":"43. Mikulska M, Raiola AM, Signori A, et al. Screening with serum galactomannan might be associated with better outcome than symptom-triggered galactomannan testing in allogeneic HSCT recipients with invasive aspergillosis. Clin Infect Dis 2013;57:1786-7.","journal-title":"Clin Infect Dis"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S1473-3099(13)70076-8","article-title":"Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients: a randomised controlled trial","volume":"13","author":"Morrissey","year":"2013","unstructured":"44. Morrissey CO, Chen SCA, Sorrell TC, et al. Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients: a randomised controlled trial. Lancet Infect Dis 2013; 13:519-28.","journal-title":"Lancet Infect Dis"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1182\/blood.V86.2.813.bloodjournal862813","article-title":"Working Party Chronic Leukemia of the European Group for Blood and Marrow Transplantation","volume":"86","author":"Gratwohl","year":"1995","unstructured":"45. Gratwohl A, Hermans J, Apperley J, et al. Acute graft-versus-host disease: grade and outcome in patients with chronic myelogenous leukemia. Working Party Chronic Leukemia of the European Group for Blood and Marrow Transplantation. Blood 1995; 86:813-18.","journal-title":"Blood"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1111\/j.1365-2796.2012.02547.x","article-title":"Bone marrow or peripheral blood stem cell transplantation from unrelated donors in adult patients with acute myeloid leukaemia, an Acute Leukaemia Working Party analysis in 2262 patients","volume":"272","author":"Ringd\u00e9n","year":"2012","unstructured":"46. Ringd\u00e9n O, Labopin M, Beelen DW, et al. Bone marrow or peripheral blood stem cell transplantation from unrelated donors in adult patients with acute myeloid leukaemia, an Acute Leukaemia Working Party analysis in 2262 patients. J Intern Med 2012;272:472-83.","journal-title":"J Intern Med"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1038\/sj.bmt.1705852","article-title":"Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation","volume":"40","author":"Pollyea","year":"2007","unstructured":"47. Pollyea DA, Artz AS, Stock W, et al. Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2007;40: 1027-32.","journal-title":"Bone Marrow Transplant"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1038\/leu.2011.351","article-title":"An analysis on behalf of the Acute Leukemia Working Party of EBMT","volume":"26","author":"Spyridonidis","year":"2012","unstructured":"48. Spyridonidis A, Labopin M, Schmid C, et al. Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMT. Leukemia 2012;26:1211-17.","journal-title":"Leukemia"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"49. Wu C. Immunologic targeting of the cancer stem cell. StemBook [Internet]. Cambridge (MA): Harvard Stem Cell Institute; 2008. Available at: http:\/\/www.stembook. org\/node\/529","DOI":"10.3824\/stembook.1.21.1"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1126\/science.1079490","article-title":"Control of regulatory T cell development by the transcription factor Foxp3","volume":"299","author":"Hori","year":"2003","unstructured":"50. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003;299:1057-61.","journal-title":"Science"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1084\/jem.20060468","article-title":"Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells","volume":"203","author":"Seddiki","year":"2006","unstructured":"51. Seddiki N, Santner-Nanan B, Martinson J, et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 2006;203:1693-700.","journal-title":"J Exp Med"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/nri2343","article-title":"How regulatory T cells work","volume":"8","author":"Vignali","year":"2008","unstructured":"52. Vignali DAA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol 2008;8:523-32.","journal-title":"Nat Rev Immunol"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"4216","DOI":"10.1182\/blood-2004-01-0005","article-title":"Induction of antigen-specific tolerance to bone marrow allografts with CD4+CD25+ T lymphocytes","volume":"103","author":"Joffre","year":"2004","unstructured":"53. Joffre O, Gorsse N, Romagnoli P, Hudrisier D, Van Meerwijk JP. Induction of antigen-specific tolerance to bone marrow allografts with CD4+CD25+ T lymphocytes. Blood 2004;103:4216-21.","journal-title":"Blood"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1084\/jem.20020399","article-title":"Donor-type CD4+CD25+ regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation","volume":"196","author":"Hoffmann","year":"2002","unstructured":"54. Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S. Donor-type CD4+CD25+ regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med 2002;196:389-99.","journal-title":"J Exp Med"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1182\/blood-2007-07-103895","article-title":"The impact of regulatory T cells on T-cell immunity following hematopoietic cell transplantation","volume":"111","author":"Nguyen","year":"2008","unstructured":"55. Nguyen VH, Shashidhar S, Chang DS, et al. The impact of regulatory T cells on T-cell immunity following hematopoietic cell transplantation. Blood 2008;111:945-53.","journal-title":"Blood"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1182\/blood-2010-07-293795","article-title":"Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics","volume":"117","author":"Brunstein","year":"2011","unstructured":"56. Brunstein CG, Miller JS, Cao Q, et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood 2011;117:1061-70.","journal-title":"Blood"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.coi.2011.06.006","article-title":"Regulatory T cells in stem cell transplantation: strategies and first clinical experiences","volume":"23","author":"Edinger","year":"2011","unstructured":"57. Edinger M, Hoffmann P. Regulatory T cells in stem cell transplantation: strategies and first clinical experiences. Curr Opin Immunol 2011;23:679-84.","journal-title":"Curr Opin Immunol"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.clim.2009.06.001","article-title":"First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127\u2212 T regulatory cells","volume":"133","author":"Trzonkowski","year":"2009","unstructured":"58. Trzonkowski P, Bieniaszewska M, Ju\u015bci\u0144ska J, et al. First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127\u2212 T regulatory cells. Clin Immunol 2009;133:22-6.","journal-title":"Clin Immunol"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"3921","DOI":"10.1182\/blood-2010-10-311894","article-title":"Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation","volume":"117","author":"Di Ianni","year":"2011","unstructured":"59. Di Ianni M, Falzetti F, Carotti A, et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 2011;117:3921-8.","journal-title":"Blood"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1182\/blood-2014-03-564401","article-title":"HLA-haploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse","volume":"124","author":"Martelli","year":"2014","unstructured":"60. Martelli MF, Ianni MD, Ruggeri L, et al. HLA-haploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse. Blood 2014;124:638-44.","journal-title":"Blood"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/nri3212","article-title":"Advances in graft-versus-host disease biology and therapy","volume":"12","author":"Blazar","year":"2012","unstructured":"61. Blazar BR, Murphy WJ, Abedi M. Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol 2012;12:443-58.","journal-title":"Nat Rev Immunol"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nri2781","article-title":"\u03b3\u03b4 T cell effector functions: a blend of innate programming and acquired plasticity","volume":"10","author":"Bonneville","year":"2010","unstructured":"62. Bonneville M, O'Brien RL, Born WK. \u03b3\u03b4 T cell effector functions: a blend of innate programming and acquired plasticity. Nat Rev Immunol 2010;10:467-78.","journal-title":"Nat Rev Immunol"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/sj.bmt.1705650","article-title":"Long term disease-free survival in acute leukemia patients recovering with increased \u03b3\u03b4 T cells after partially mismatched related donor","volume":"39","author":"Godder","year":"2007","unstructured":"63. Godder KT, Henslee-Downey PJ, Mehta J, et al. Long term disease-free survival in acute leukemia patients recovering with increased \u03b3\u03b4 T cells after partially mismatched related donor. Bone Marrow Transplant 2007;39:751-7.","journal-title":"Bone Marrow Transplant"},{"key":"ref63","doi-asserted-by":"publisher","unstructured":"64. Bertaina A, Romano M, Rutella S, et al. HLA haploidentical stem cell transplantation after removal of alpha beta + T lymphocytes and B lymphocytes is an effective treatment for children with life-threatening, non-malignant disorders. American Society of Hematology Annual Meeting Abstracts 2012;120: 2018. Available at: https:\/\/ash.confex.com\/ash\/ 2012\/webprogram\/Paper48341.html (Accessed Aug 28, 2014).","DOI":"10.1182\/blood.V120.21.2018.2018"},{"key":"ref64","doi-asserted-by":"publisher","unstructured":"65. Handgretinger R, Lang P, Feuchtinger TF, et al. Transplantation of TcR {alpha}{beta}\/CD19 depleted stem cells from haploidentical donors: robust engraftment and rapid immune reconstitution in children with high risk leukemia. American Society of Hematology Annual Meeting Abstracts. 2011;118: 1005. Available at: https:\/\/ash.confex.com\/ash\/ 2011\/webprogram\/Paper40225.html (Accessed Aug 28, 2014).","DOI":"10.1182\/blood.V118.21.1005.1005"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1182\/blood-2008-06-164103","article-title":"Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity","volume":"113","author":"Pende","year":"2009","unstructured":"66. Pende D, Marcenaro S, Falco M, et al. Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity. Blood 2009;113:3119-29.","journal-title":"Blood"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/bmt.2012.162","article-title":"Pre-emptive immunotherapy with purified natural killer cells after haploidentical SCT: a prospective phase II study in two centers","volume":"48","author":"Stern","year":"2013","unstructured":"67. Stern M, Passweg JR, Meyer-Monard S, et al. Pre-emptive immunotherapy with purified natural killer cells after haploidentical SCT: a prospective phase II study in two centers. Bone Marrow Transplant 2013;48:433-8.","journal-title":"Bone Marrow Transplant"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1182\/asheducation-2011.1.299","article-title":"Post transplantation vaccination: concepts today and on the horizon","volume":"2011","author":"Rezvani","year":"2011","unstructured":"68. Rezvani K. Post transplantation vaccination: concepts today and on the horizon. Hematology Am Soc Hematol Educ Program 2011;2011:299-304.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1182\/blood-2010-04-277137","article-title":"Vaccination with dendritic cell\/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma","volume":"117","author":"Rosenblatt","year":"2011","unstructured":"69. Rosenblatt J, Vasir B, Uhl L, et al. Vaccination with dendritic cell\/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma. Blood 2011;117:393-402.","journal-title":"Blood"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"15825","DOI":"10.1073\/pnas.0908358106","article-title":"Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation","volume":"106","author":"VT","year":"2009","unstructured":"70. Ho VT, Vanneman M, Kim H, et al. Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation. Proc Natl Acad Sci U S A 2009;106: 15825-30.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"3756","DOI":"10.1172\/JCI69098","article-title":"Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells","volume":"123","author":"Burkhardt","year":"2013","unstructured":"71. Burkhardt UE, Hainz U, Stevenson K, et al. Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells. J Clin Invest 2013;123:3756-65.","journal-title":"J Clin Invest"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1038\/sj.bmt.1702399","article-title":"Infusion of lymphocytes obtained from a donor immunised with the paraprotein idiotype as a treatment in a relapsed myeloma","volume":"25","author":"Cabrera","year":"2000","unstructured":"72. Cabrera R, Diaz-Espada F, Barrios Y, et al. Infusion of lymphocytes obtained from a donor immunised with the paraprotein idiotype as a treatment in a relapsed myeloma. Bone Marrow Transplant 2000;25:1105-8.","journal-title":"Bone Marrow Transplant"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/S0140-6736(95)90757-2","article-title":"Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor","volume":"345","author":"Kwak","year":"1995","unstructured":"73. Kwak LW, Duffey PL, Reynolds CW, et al. Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor. Lancet 1995;345:1016-20.","journal-title":"Lancet"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/sj.bmt.1705057","article-title":"Tumor antigen immunization of sibling stem cell transplant donors in multiple myeloma","volume":"36","author":"Neelapu","year":"2005","unstructured":"74. Neelapu SS, Munshi NC, Jagannath S, et al. Tumor antigen immunization of sibling stem cell transplant donors in multiple myeloma. Bone Marrow Transplant 2005;36:315-23.","journal-title":"Bone Marrow Transplant"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"3924","DOI":"10.1200\/JCO.2012.42.2964","article-title":"Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia","volume":"30","author":"Burnett","year":"2012","unstructured":"75. Burnett AK, Russell NH, Hills RK, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol 2012;30:3924-31.","journal-title":"J Clin Oncol"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s13554-013-0008-7","article-title":"Brentuximab vedotin in CD30+ lymphomas","volume":"3","author":"GF","year":"2013","unstructured":"76. Perini GF, Pro B. Brentuximab vedotin in CD30+ lymphomas. Biol Ther 2013;3:15-23.","journal-title":"Biol Ther"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"5185","DOI":"10.1182\/blood-2012-07-441030","article-title":"Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL","volume":"120","author":"Topp","year":"2012","unstructured":"77. Topp MS, G\u00f6kbuget N, Zugmaier G, et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood 2012;120:5185-7.","journal-title":"Blood"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1038\/leu.2012.341","article-title":"T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33\/CD3-bispecific BiTE antibody construct","volume":"27","author":"Aigner","year":"2013","unstructured":"78. Aigner M, Feulner J, Schaffer S, et al. T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33\/CD3-bispecific BiTE antibody construct. Leukemia 2013;27:1107-15.","journal-title":"Leukemia"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1038\/leu.2013.18","article-title":"Redirection of T cells with a first fully humanized bispecific CD33-CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cells","volume":"27","author":"Arndt","year":"2013","unstructured":"79. Arndt C, von Bonin M, Cartellieri M, et al. Redirection of T cells with a first fully humanized bispecific CD33-CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cells. Leukemia 2013;27:964-7.","journal-title":"Leukemia"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/bjh.12691","article-title":"Antibody therapy for acute myeloid leukaemia","volume":"164","author":"Gasiorowski","year":"2014","unstructured":"80. Gasiorowski RE, Clark GJ, Bradstock K, Hart DNJ. Antibody therapy for acute myeloid leukaemia. Br J Haematol 2014;164:481-95.","journal-title":"Br J Haematol"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor (CAR) design","volume":"3","author":"Sadelain","year":"2013","unstructured":"81. Sadelain M, Brentjens R, Riviere I. The basic principles of chimeric antigen receptor (CAR) design. Cancer Discov 2013;3:388-98.","journal-title":"Cancer Discov"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"4099","DOI":"10.1182\/blood-2010-04-281931","article-title":"Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19","volume":"116","author":"Kochenderfer","year":"2010","unstructured":"82. Kochenderfer JN, Wilson WH, Janik JE, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010;116:4099-102.","journal-title":"Blood"},{"key":"ref82","doi-asserted-by":"publisher","unstructured":"83. Brentjens R, Davila ML, Riviere I, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 2013;5:177ra38.","DOI":"10.1126\/scitranslmed.3005930"},{"key":"ref83","doi-asserted-by":"publisher","unstructured":"84. Kalos M, Levine BL, Porter DL, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. SciTransl Med 2011;3:95ra73.","DOI":"10.1126\/scitranslmed.3002842"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","unstructured":"85. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011;365:725-33.","journal-title":"N Engl J Med"},{"key":"ref85","doi-asserted-by":"publisher","unstructured":"86. Mardiros A, Brown CE, Budde LE, Wang X, Forman SJ. Acute myeloid leukemia therapeutics. Oncoimmunology 2013;2:e27214.","DOI":"10.4161\/onci.27214"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/bjh.12282","article-title":"Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor","volume":"161","author":"Tettamanti","year":"2013","unstructured":"87. Tettamanti S, Marin V, Pizzitola I, et al. Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor. Br J Haematol 2013;161:389-401.","journal-title":"Br J Haematol"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"384","DOI":"10.3109\/07853890.2014.918463","article-title":"The expanding horizon of immunotherapy in the treatment of malignant disorders: allogeneic hematopoietic stem cell transplantation and beyond","volume":"46","author":"Tsirigotis","year":"2014","unstructured":"88. Tsirigotis P, Shimoni A, Nagler A. The expanding horizon of immunotherapy in the treatment of malignant disorders: allogeneic hematopoietic stem cell transplantation and beyond. Ann Med 2014;46: 384-96.","journal-title":"Ann Med"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1182\/blood-2005-01-0393","article-title":"Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation","volume":"106","author":"Solomon","year":"2005","unstructured":"89. Solomon SR, Mielke S, Savani BN, et al. Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation. Blood 2005;106: 1123-9.","journal-title":"Blood"},{"key":"ref89","doi-asserted-by":"publisher","unstructured":"90. Roy DC, Guerin M, Boumedine RS, et al. Reduction in incidence of severe infections by transplantation of high doses of haploidentical T cells selectively depleted of alloreactive units [abstract]. American Society of Hematology Annual Meeting Abstracts. 2011;118:3020. Available at: https:\/\/ash.confex.com\/ ash\/2011\/webprogram\/Paper41067.html (Accessed Aug 28, 2014).","DOI":"10.1182\/blood.V118.21.3020.3020"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1111\/j.1365-2141.2008.07316.x","article-title":"Cytotoxic T lymphocytes as immune-therapy in haematological practice","volume":"143","author":"AM","year":"2008","unstructured":"91. Leen AM, Heslop HE. Cytotoxic T lymphocytes as immune-therapy in haematological practice. Br J Haematol 2008;143:169-79.","journal-title":"Br J Haematol"},{"key":"ref91","unstructured":""}],"container-title":["Rambam Maimonides Medical Journal"],"original-title":[],"link":[{"URL":"https:\/\/www.rmmj.org.il\/userimages\/426\/1\/PublishFiles\/444Article.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T09:08:03Z","timestamp":1791709683000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.rmmj.org.il\/issues\/23\/Articles\/444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,29]]},"references-count":92,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2014,10,29]]}},"URL":"https:\/\/doi.org\/10.5041\/rmmj.10162","relation":{},"ISSN":["2076-9172"],"issn-type":[{"value":"2076-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,29]]}}}